Cargando…

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition

BACKGROUND: Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in patients with refractory chronic lymphocy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Wenjun, Ji, Jia, Dai, Zunyan, Papp, Audrey, Johnson, Amy J., Ahn, Sunjoo, Farley, Katherine L., Lin, Thomas S., Dalton, James T., Li, Xiaobai, Jarjoura, David, Byrd, John C., Sadee, Wolfgang, Grever, Michael R., Phelps, Mitch A.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967470/ https://www.ncbi.nlm.nih.gov/pubmed/21072184 http://dx.doi.org/10.1371/journal.pone.0013792

Ejemplares similares

Potent interaction of flavopiridol with MRP1
por: Hooijberg, J H, et al.
Publicado: (1999)

Effect of P-glycoprotein on flavopiridol sensitivity
por: Boerner, S A, et al.
Publicado: (2001)

The Pharmacological Implications of Flavopiridol: An Updated Overview
por: Joshi, Hemant, et al.
Publicado: (2023)

Transgenic models are predictive: the herceptin and flavopiridol experience
por: Schmidt, E
Publicado: (2003)

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
por: Blum, Kristie A., et al.
Publicado: (2011)

Complex effects of flavopiridol on the expression of primary response genes
por: Keskin, Havva, et al.
Publicado: (2012)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
por: Rodrigues, Alice C., et al.
Publicado: (2011)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
por: Bins, S, et al.
Publicado: (2017)

Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
por: Hu, Zi’ang, et al.
Publicado: (2018)

Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
por: Cimica, Velasco, et al.
Publicado: (2010)

The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109
por: YAO, YUAN, et al.
Publicado: (2013)

Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
por: Li, Xiaoran, et al.
Publicado: (2017)

Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells
por: Brännström, Marie, et al.
Publicado: (2015)

The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
por: Zocchi, Loredana, et al.
Publicado: (2018)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
por: Taylor, Zachary L., et al.
Publicado: (2021)

Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
por: Häkkinen, Katja, et al.
Publicado: (2023)

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma
por: Morris, Don G., et al.
Publicado: (2006)

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol
por: Lam, Lloyd T, et al.
Publicado: (2001)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2021)

Commentary on: “Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide”
por: Morrissey, KM, et al.
Publicado: (2017)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
por: Li, Qian, et al.
Publicado: (2019)

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
por: Nilubol, Naris, et al.
Publicado: (2018)

Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models
por: Pinto, Nicole, et al.
Publicado: (2020)

Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9
por: Jia, Qi, et al.
Publicado: (2022)

Structure of human drug transporters OATP1B1 and OATP1B3
por: Ciută, Anca-Denise, et al.
Publicado: (2023)

Ribosome biogenesis mediates antitumor activity of flavopiridol in CD44(+)/CD24(−) breast cancer stem cells
por: Erol, Ayse, et al.
Publicado: (2017)

Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
por: Saisomboon, Saowaluk, et al.
Publicado: (2019)

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
por: Nies, Anne T, et al.
Publicado: (2013)

Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions
por: Kayesh, Ruhul, et al.
Publicado: (2023)

Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach
por: George Priya Doss, C, et al.
Publicado: (2013)

Effects of flavopiridol on critical regulation pathways of CD133(high)/CD44(high) lung cancer stem cells
por: Bozok Cetintas, Vildan, et al.
Publicado: (2016)

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex
por: Biglione, Sebastian, et al.
Publicado: (2007)

SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study
por: Luo, Jian-Quan, et al.
Publicado: (2015)

Induced growth inhibition, cell cycle arrest and apoptosis in CD133(+)/CD44(+) prostate cancer stem cells by flavopiridol
por: SONER, BURAK CEM, et al.
Publicado: (2014)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines
por: Haberkorn, Bastian, et al.
Publicado: (2023)

Selectivity and Potency of Microcystin Congeners against OATP1B1 and OATP1B3 Expressing Cancer Cells
por: Niedermeyer, Timo H. J., et al.
Publicado: (2014)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tl33dhsnjpienn7ech06141tom